CVE-2023-40153

Published: Oct 19, 2023Modified: Nov 21, 2024

6.1

Vector

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Exploitability: 2.8 / Impact: 2.7

Source: NVD

Description

The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload into the 'hostname' parameter of the vulnerable software.

Affected (1)

Products: Dexma: Dexgate

1 product

Configuration A

1 vulnerable

Vulnerable Software	Affected Versions
Dexma Dexgate	Version 20130114

Related CWEs

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')

The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users.

References (2)

https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02

Source: ics-cert@hq.dhs.gov

Third Party AdvisoryUS Government Resource

https://www.cisa.gov/news-events/ics-advisories/icsa-23-271-02

Source: af854a3a-2127-422b-91ae-364da2661108

Third Party AdvisoryUS Government Resource

Timeline

No history available yet.